Strain Name:

STOCK Tg(tetO-SNCA*A53T)E2Cai/J

Stock Number:

012442

Order this mouse

Availability:

Cryopreserved - Ready for recovery

Use Restrictions Apply, see Terms of Use
These transgenic mice carry a humanized synuclein (alpha-syn) mutant (SNCA*A53T) gene regulated by a tetracycline operator (tetO). When mated to a mutant strain expressing tTA, expression of SNCA*A53T protein may be regulated with the tetracycline analog doxycycline in the double mutant offspring.

Description

The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.

Strain Information

Former Names C57BL/6J-Tg(tetO-SNCA*A53T)E2Cai/J    (Changed: 22-SEP-11 )
Type Mutant Stock; Transgenic;
Additional information on Genetically Engineered and Mutant Mice.
Visit our online Nomenclature tutorial.
Specieslaboratory mouse
 
Donating Investigator Huaibin Cai,   NIA

Description
Mice hemizygous for the human synuclein (alpha-syn) mutant transgene, (SNCA*A53T) are viable and fertile. Expression of SNCA*A53T is regulated by the tetracycline operator (tetO); also called tetracycline-responsive element (TRE, TetRE) or tet-operator). When mated to a mutant strain expressing tetracycline-controlled transactivator protein (tTA), expression of SNCA*A53T protein may be regulated with tetracycline or its analog doxycycline (dox) in the double mutant offspring. Mutations in alpha-syn greatly accelerate the formation of fibrillar aggregates causing various forms of cytotoxicity, including impairment of proteasomal and lysosomal activities, disruption of ER-Golgi traffic and microtubule-based transport, and dysfunction of mitochondria. SNCA*A53T mice develop age-dependent, progressive neurodegeneration. These mice may be useful for studying the Parkinson's disease pathogenesis and neurodegeneration elicited by the toxic effects of aggregation and somatic accumulation of SNCA.

Development
A transgene was generated encoding a human SNCA*A53T mutant gene under control of a tetO promoter. The construct was microinjected into C57BL/6J fertilized oocytes, and founder mice were bred to C57BL/6J mice to establish a colony. Upon arrival at The Jackson Laboratory, mice were bred to C57BL/6J inbred mice (Stock No. 000664) for at least one generation to establish the colony.

A 32 SNP (single nucleotide polymorphism) panel analysis performed by The Jackson Laboratory revealed 10 of 32 markers (on six different chromosomes) that were not C57BL/6J allele-type. These data suggest C57BL/6N, FVB, and/or other genetic contamination prior to arrival at The Jackson Laboratory.

Control Information

  Control
   Wild-type from the colony
 
  Considerations for Choosing Controls

Related Strains

Parkinson's Disease Models
005987   129-Achetm1Loc/J
007587   129S-Park2tm1Rpa/J
002779   129S-Parp1tm1Zqw/J
016198   129S6.Cg-Tg(Camk2a-tTA)1Mmay/JlwsJ
004608   B6(Cg)-Htra2mnd2/J
008133   B6.129-Sncbtm1Sud/J
008084   B6.129P2-Drd4tm1Dkg/J
004744   B6.129P2-Esr1tm1Ksk/J
013586   B6.129P2-Gt(ROSA)26Sortm1Nik/J
002609   B6.129P2-Nos2tm1Lau/J
008843   B6.129P2-Sncgtm1Vlb/J
016566   B6.129S-Hcn1tm2Kndl/J
004322   B6.129S1-Mapk10tm1Flv/J
003190   B6.129S2-Drd2tm1Low/J
006582   B6.129S4-Park2tm1Shn/J
005934   B6.129S4-Ucp2tm1Lowl/J
004936   B6.129S6(Cg)-Spp1tm1Blh/J
012453   B6.129X1(FVB)-Lrrk2tm1.1Cai/J
017009   B6.129X1-Nfe2l2tm1Ywk/J
009346   B6.Cg-Lrrk2tm1.1Shn/J
005491   B6.Cg-Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/J
006577   B6.Cg-Park7tm1Shn/J
000567   B6.Cg-T2J +/+ Qkqk-v/J
007004   B6.Cg-Tg(Camk2a-tTA)1Mmay/DboJ
003139   B6.Cg-Tg(DBHn-lacZ)8Rpk/J
007673   B6.Cg-Tg(Gad1-EGFP)3Gfng/J
012466   B6.Cg-Tg(Lrrk2)6Yue/J
012467   B6.Cg-Tg(Lrrk2*G2019S)2Yue/J
008323   B6.Cg-Tg(Mc4r-MAPT/Sapphire)21Rck/J
008321   B6.Cg-Tg(Npy-MAPT/Sapphire)1Rck/J
008324   B6.Cg-Tg(Pmch-MAPT/CFP)1Rck/J
008322   B6.Cg-Tg(Pomc-MAPT/Topaz)1Rck/J
007894   B6.Cg-Tg(Rgs4-EGFP)4Lvt/J
012588   B6.Cg-Tg(TH-ALPP)1Erav/J
008859   B6.Cg-Tg(THY1-SNCA*A53T)F53Sud/J
008135   B6.Cg-Tg(THY1-SNCA*A53T)M53Sud/J
008601   B6.Cg-Tg(Th-cre)1Tmd/J
013583   B6.Cg-Tg(tetO-LRRK2)C7874Cai/J
000544   B6.D2-Cacna1atg/J
012445   B6.FVB-Tg(LRRK2)WT1Mjfa/J
012446   B6.FVB-Tg(LRRK2*G2019S)1Mjfa/J
006660   B6.SJL-Slc6a3tm1.1(cre)Bkmn/J
008364   B6;129-Chattm1(cre/ERT)Nat/J
009688   B6;129-Dbhtm2(Th)Rpa Thtm1Rpa/J
008883   B6;129-Gt(ROSA)26Sortm1(SNCA*A53T)Djmo/TmdJ
008889   B6;129-Gt(ROSA)26Sortm2(SNCA*119)Djmo/TmdJ
008886   B6;129-Gt(ROSA)26Sortm3(SNCA*E46K)Djmo/TmdJ
009347   B6;129-Lrrk2tm1.1Shn/J
016209   B6;129-Lrrk2tm2.1Shn/J
016210   B6;129-Lrrk2tm3.1Shn/J
013050   B6;129-Pink1tm1Aub/J
004807   B6;129-Psen1tm1Mpm Tg(APPSwe,tauP301L)1Lfa/Mmjax
006390   B6;129-Sncatm1Sud Sncbtm1.1Sud/J
008532   B6;129-Thtm1(cre/Esr1)Nat/J
008333   B6;129P2-Dldtm1Ptl/J
008333   B6;129P2-Dldtm1Ptl/J
002596   B6;129P2-Nos2tm1Lau/J
003243   B6;129S-Tnfrsf1atm1Imx Tnfrsf1btm1Imx/J
003692   B6;129X1-Sncatm1Rosl/J
016575   B6;C3-Tg(PDGFB-LRRK2*G2019S)340Djmo/J
016576   B6;C3-Tg(PDGFB-LRRK2*R1441C)574Djmo/J
008169   B6;C3-Tg(Prnp-MAPT*P301S)PS19Vle/J
004479   B6;C3-Tg(Prnp-SNCA*A53T)83Vle/J
000231   B6;C3Fe a/a-Csf1op/J
013725   B6;SJL-Tg(LRRK2)66Youy/J
016555   B6;SJL-Tg(Nqo1-ALPP)1Jaj/J
008473   B6;SJL-Tg(THY1-SNCA*A30P)M30Sud/J
008134   B6;SJL-Tg(THY1-SNCA*A30P)TS2Sud/J
016976   B6C3-Tg(tetO-SNCA*A53T)33Vle/J
000506   B6C3Fe a/a-Qkqk-v/J
003741   B6D2-Tg(Prnp-MAPT)43Vle/J
012621   C.129S(B6)-Chrna3tm1.1Hwrt/J
008389   C57BL/6-Tg(THY1-SNCA)1Sud/J
012769   C57BL/6-Tg(Thy1-Sncg)HvP36Putt/J
005706   C57BL/6-Tg(tetO-CDK5R1/GFP)337Lht/J
006618   C57BL/6-Tg(tetO-COX8A/EYFP)1Ksn/J
008245   C57BL/6J-Tg(Th-SNCA)5Eric/J
008239   C57BL/6J-Tg(Th-SNCA*A30P*A53T)39Eric/J
012441   C57BL/6J-Tg(tetO-LRRK2*G2019S)E3Cai/J
012450   C57BL/6J-Tg(tetO-SNCA)1Cai/J
016120   C57BL/6N-Lrrk1tm1.1Youy/J
016121   C57BL/6N-Lrrk2tm1.1Youy/J
016936   C57BL/6N-Tg(Thy1-SNCA)12Youy/J
017682   C57BL/6N-Tg(Thy1-SNCA)15Youy/J
007677   CB6-Tg(Gad1-EGFP)G42Zjh/J
009610   FVB/N-Tg(LRRK2)1Cjli/J
009609   FVB/N-Tg(LRRK2*G2019S)1Cjli/J
009604   FVB/N-Tg(LRRK2*R1441G)135Cjli/J
009090   FVB/NJ-Tg(Slc6a3-PARK2*Q311X)AXwy/J
010710   FVB;129S6-Sncatm1Nbm Tg(SNCA)1Nbm/J
010788   FVB;129S6-Sncatm1Nbm Tg(SNCA*A30P)1Nbm Tg(SNCA*A30P)2Nbm/J
010799   FVB;129S6-Sncatm1Nbm Tg(SNCA*A53T)1Nbm Tg(SNCA*A53T)2Nbm/J
004808   STOCK Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/J
000942   STOCK Pitx3ak/2J
014092   STOCK Tg(ACTB-tTA2,-MAPT/lacZ)1Luo/J
006340   STOCK Tg(Gad1-EGFP)98Agmo/J
008474   STOCK Tg(THY1-SNCA*A53T)F53Sud/J
008132   STOCK Tg(THY1-Snca)M1mSud/J
012449   STOCK Tg(teto-LRRK2)C7874Cai/J
View Parkinson's Disease Models     (99 strains)

View Strains carrying other alleles of SNCA     (15 strains)

Strains carrying other alleles of tetO
008079   129S-Ppargtm2Yba/J
009602   B6.129S4(Cg)-Kcnn2tm2Jpad/J
009603   B6.129S4-Kcnn3tm1Jpad/J
006361   B6.Cg-Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/J
016998   B6.Cg-Tg(TetO-Axin1,EGFP)TA6Cos/J
003762   B6.Cg-Tg(tetFosb)4468Nes/J
007051   B6.Cg-Tg(tetO-APPSwInd)102Dbo/Mmjax
007052   B6.Cg-Tg(tetO-APPSwInd)107Dbo/Mmjax
007049   B6.Cg-Tg(tetO-APPSwInd)885Dbo/Mmjax
007618   B6.Cg-Tg(tetO-Arntl)1Jt/J
008277   B6.Cg-Tg(tetO-Clockm1Jt)CL57Jt/J
008468   B6.Cg-Tg(tetO-DTA)1Gfi/J
009344   B6.Cg-Tg(tetO-Ifng)184Pop/J
009136   B6.Cg-Tg(tetO-Kcnj2,lacZ)1Gogo/J
013583   B6.Cg-Tg(tetO-LRRK2)C7874Cai/J
006234   B6.Cg-Tg(tetO-cre)1Jaw/J
005738   B6.FVB-Tg(tetO-EGFP,-Tgfbr2)8Mcle/J
006911   B6;129-Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm2(tetO-Pou5f1)Jae/J
012433   B6;C3-Tg(ACTA1-rtTA,tetO-cre)102Monk/J
002709   B6;C3-Tg(TettTALuc)1Dgs/J
016841   B6;C3-Tg(tetO-TARDBP)12Vle/J
014650   B6;C3-Tg(tetO-TARDBP*)4Vle/J
008344   B6;DBA-Tg(Fos-tTA,Fos-EGFP*)1Mmay Tg(tetO-lacZ,tTA*)1Mmay/J
008082   B6;SJL-Tg(Tagln-tTA)1Mrab Tg(tetO-Mcpt1)1Mrab/J
010575   B6;SJL-Tg(tetO-Egfr*)2-9Jek/J
010577   B6;SJL-Tg(tetO-Erbb2*)8-4Jek/J
002621   B6;SJL-Tg(tetop-lacZ)2Mam/J
006004   B6C3-Tg(tetO-APPSwInd)885Dbo/Mmjax
016976   B6C3-Tg(tetO-SNCA*A53T)33Vle/J
006244   C.Cg-Tg(tetO-cre)1Jaw/J
005706   C57BL/6-Tg(tetO-CDK5R1/GFP)337Lht/J
006618   C57BL/6-Tg(tetO-COX8A/EYFP)1Ksn/J
013729   C57BL/6-Tg(tetO-EDN1,-lacZ)9Mhus/J
010713   C57BL/6-Tg(tetO-GFP/tetX)5696Stl/J
013728   C57BL/6-Tg(tetO-NOS2,-lacZ)240iMhus/J
016181   C57BL/6-Tg(tetO-Nr1d1)1Schb/J
008278   C57BL/6J-Tg(tetO-Clock)1Jt/J
012441   C57BL/6J-Tg(tetO-LRRK2*G2019S)E3Cai/J
012450   C57BL/6J-Tg(tetO-SNCA)1Cai/J
017542   FVB-Tg(Myh6/tetO-ATP2B4)1Jmol/J
016571   FVB-Tg(Myh6/tetO-Gata6)2Jmol/J
014155   FVB-Tg(Myh6/tetO-Itpr1)22.3Jmol/J
014153   FVB-Tg(Myh6/tetO-Itpr2)3.11Jmol/J
014154   FVB-Tg(Myh6/tetO-Itpr2)4.9Jmol/J
012684   FVB-Tg(Myh6/tetO-POSTN)22.1Jmol/J
010580   FVB-Tg(Myh6/tetO-PRKCA*)1Jmk/J
013156   FVB-Tg(tetO-CDK5R1*)1Vln/J
013778   FVB-Tg(tetO-Cacnb2)1Jmol/J
013779   FVB-Tg(tetO-Cacnb2)2Jmol/J
013780   FVB-Tg(tetO-Cib1)1Jmol/J
010578   FVB-Tg(tetO-Dusp6)1Jmol/J
008685   FVB-Tg(tetO-Kdr*)4377.5Rwng/J
015815   FVB-Tg(tetO-MAPT*P301L)#Kha/J
008695   FVB-Tg(tetO-MET)23Rwng/J
012387   FVB-Tg(tetO-Ppargc1a)1Dpk/J
012385   FVB-Tg(tetO-Ppargc1b)7Dpk/J
006439   FVB-Tg(tetO/CMV-KRAS*G12C)9.1Msmi/J
008244   FVB.Cg-Tg(tetO-cre)1Jaw/J
012459   FVB/N-Tg(Myh6*/tetO-Capn1)L2Gwd/J
005941   FVB/N-Tg(tetO-Aurkb,lacZ)41Kra/J
006202   FVB/N-Tg(tetO-BCR/ABL1)2Dgt/J
014547   FVB/N-Tg(tetO-Fasl)BDepa/J
003315   FVB/N-Tg(tetORo1-lacZ)3Conk/J
005076   NOD.Cg-Tg(tetO-EGFP/FADD)1Doi/DoiJ
006999   STOCK Dbttm1Geh Tg(Cebpb-tTA)5Bjd Tg(tetO-DBT)A1Geh/J
015838   STOCK Tg(Camk2a-tTA)1Mmay Tg(tetO-ABL1*P242E*P249E)CPdav/J
008755   STOCK Tg(Ins2-rtTA)2Efr Tg(teto-DTA)1Gfi/J
012477   STOCK Tg(Myh6*/tetO-GCaMP2)1Mik/J
016572   STOCK Tg(Myh6/tetO-Gata4)1Jmol/J
014544   STOCK Tg(tetO-ABL1*P242E*P249E)CPdav/J
014093   STOCK Tg(tetO-CHRM3*)1Blr/J
008790   STOCK Tg(tetO-DISC1*)1001Plet/J
008168   STOCK Tg(tetO-DTA)1Gfi/J
017755   STOCK Tg(tetO-GCAMP2)12iRyu/J
005104   STOCK Tg(tetO-HIST1H2BJ/GFP)47Efu/J
005699   STOCK Tg(tetO-Ipf1,EGFP)956.6Macd/J
005728   STOCK Tg(tetO-Ipf1,lacZ)958.1Macd/J
006224   STOCK Tg(tetO-cre)1Jaw/J
012345   STOCK Tg(tetO-tdTomato,-Syp/EGFP*)1.1Luo/J
012449   STOCK Tg(teto-LRRK2)C7874Cai/J
View Strains carrying other alleles of tetO     (80 strains)

Additional Web Information

Tet Expression Systems

Visit the Parkinson's Disease Resource site for helpful information on Parkinson's and research resources.

Phenotype

Phenotype Information

View Mammalian Phenotype Terms

Mammalian Phenotype Terms provided by MGI
      assigned by genotype

The following phenotype relates to a compound genotype created using this strain.
Contact JAX® Services jaxservices@jax.org for customized breeding options.

Tg(Camk2a-tTA)1Mmay/0 Tg(tetO-SNCA*A53T)E2Cai/0

        involves: C57BL/6
  • growth/size phenotype
  • decreased body weight
    • A53T mice weigh significantly less than non transgenic mice and Tg(tetO-SNCA*A53T)E2Cai or Tg(Camk2a-tTA)1Mmay single mutants starting at 4 months of age   (MGI Ref ID J:156512)
  • behavior/neurological phenotype
  • abnormal locomotor activation   (MGI Ref ID J:156512)
    • hyperactivity
      • at 2 months of age, mice show drastically increased ambulatory activity   (MGI Ref ID J:156512)
    • increased vertical activity
      • mice display elevated rearing activities at 6 months of age   (MGI Ref ID J:156512)
  • nervous system phenotype
  • abnormal nervous system morphology
    • only a few neurons in the brain display alpha-synuclein staining in the cell body at 3 months; somatic accumulation becomes more prominent at 20 months; whereas no accumulation is detected in cell bodies at 1 month   (MGI Ref ID J:156512)
    • significant rescue of phenotype is observed when animals are treated with doxycycline to inhibit transgene expression   (MGI Ref ID J:156512)
    • abnormal cerebral cortex morphology
      • neuron loss is detected at 6 months and later   (MGI Ref ID J:156512)
      • in 6 month old mice but not in nontransgenic controls, elevated levels of ubiquitin are detected in somas and nuclei of cortical neurons, but   (MGI Ref ID J:156512)
    • abnormal neuron morphology
      • the Golgi complex is drastically altered in neurons at 1 month, appearing thinner and fragmented   (MGI Ref ID J:156512)
      • significant increase in Golgi fragmentation is observed at 6 months   (MGI Ref ID J:156512)
      • at 1 month, the medial/trans-Golgi in neurons is significantly altered with ratio of fragmented trans-Golgi significantly increased compared to non-transgenic animals   (MGI Ref ID J:156512)
      • significant rescue of phenotype is observed when animals are treated with doxycycline to inhibit transgene expression   (MGI Ref ID J:156512)
    • abnormal striatum morphology
      • neuron loss is detected at 6 months and later   (MGI Ref ID J:156512)
      • significant rescue of phenotype is observed when animals are treated with doxycycline to inhibit transgene expression   (MGI Ref ID J:156512)
    • alpha-synuclein inclusion body
      • a significant increase in detergent-insoluble high molecular weight (HMW) alpha synuclein is detected in 12 month old mice compared to 1 month old mice   (MGI Ref ID J:156512)
      • significant decrease in HMW alpha-synuclein in total brain homogenates is observed when animals are treated with doxycycline to inhibit transgene expression   (MGI Ref ID J:156512)
    • astrocytosis
      • significant at 12 months   (MGI Ref ID J:156512)
      • significant rescue of phenotype is observed when animals are treated with doxycycline to inhibit transgene expression   (MGI Ref ID J:156512)
    • microgliosis
      • significant at 12 months   (MGI Ref ID J:156512)
      • significant rescue of phenotype is observed when animals are treated with doxycycline to inhibit transgene expression   (MGI Ref ID J:156512)
  • abnormal nervous system physiology
    • while 3-month old A53T mice show no abnormal neuropathology, but neuropathology is evident at 12 and 20 months   (MGI Ref ID J:156512)
    • in 6 month old mice, elevated levels of ubiquitin are detected in somas and nuclei of cortical neurons; at 20 monts, a punctate staining pattern at neuronal processes is observed   (MGI Ref ID J:156512)
    • brain homogenates contain significantly elevated levels of ubiquitinated proteins at 3 months   (MGI Ref ID J:156512)
    • neurodegeneration
      • widespread degeneration is observed at 20 months   (MGI Ref ID J:156512)
      • age-dependent, progressive neurodegeneration occurs   (MGI Ref ID J:156512)
      • neuronal loss is detected in the frontal cortex (>80%) and dorsal striatum (>74%) at 20 months   (MGI Ref ID J:156512)
      • a significant reduction (>30%) of striatal neurons is seen at 6 months   (MGI Ref ID J:156512)
  • hematopoietic system phenotype
  • microgliosis
    • significant at 12 months   (MGI Ref ID J:156512)
    • significant rescue of phenotype is observed when animals are treated with doxycycline to inhibit transgene expression   (MGI Ref ID J:156512)
  • immune system phenotype
  • microgliosis
    • significant at 12 months   (MGI Ref ID J:156512)
    • significant rescue of phenotype is observed when animals are treated with doxycycline to inhibit transgene expression   (MGI Ref ID J:156512)
  • cellular phenotype
  • abnormal mitochondrial morphology
    • in striatal neurons at 1 month, numerous mitochondria have denser matrices and widened cristae compared to non-transgenic controls; these mitochondria are not functional   (MGI Ref ID J:156512)
View Research Applications

Research Applications
This mouse can be used to support research in many areas including:

Neurobiology Research
Neurodegeneration
Parkinson's Disease
      synuclein mutants
Tet Expression System
      tTA/rtTA Responsive Strains

Research Tools
Tet Expression Systems
      tTA/rtTA Responsive Strains

Genes & Alleles

Gene & Allele Information provided by MGI

 
Allele Symbol Tg(tetO-SNCA*A53T)E2Cai
Allele Name transgene insertion E2, Huaibin Cai
Allele Type Transgenic (random, expressed)
Common Name(s) alpha-syn A53T; tetO-A53T;
Mutation Made By Huaibin Cai,   NIA
Strain of OriginC57BL/6J
Expressed Gene SNCA, synuclein, alpha (non A4 component of amyloid precursor), human
Promoter tetO, tet operator,
Molecular Note A transgenic vector was generated encoding a human SNCA*A53T mutant gene under control of a tetO promoter. The construct was microinjected into C57BL/6J fertilized oocytes, and founder mice were bred to C57BL/6J mice to establish the E2 line. [MGI Ref ID J:156512]
 
 

Genotyping

Genotyping Information

Genotyping Protocols

Tg(tetO-SNCA*A53T), Standard PCR


Helpful Links

Genotyping resources and troubleshooting

References

References provided by MGI

Selected Reference(s)

Lin X; Parisiadou L; Gu XL; Wang L; Shim H; Sun L; Xie C; Long CX; Yang WJ; Ding J; Chen ZZ; Gallant PE; Tao-Cheng JH; Rudow G; Troncoso JC; Liu Z; Li Z; Cai H. 2009. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron 64(6):807-27. [PubMed: 20064389]  [MGI Ref ID J:156512]

Health & husbandry

The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.

Health & Colony Maintenance Information

Animal Health Reports

Production of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, RG10/RG30.

Colony Maintenance

Breeding & HusbandryWhen maintained as a live colony, homozygous mice may be bred together or transgene carrier mice may be bred to wild type siblings.

Purchasing information

Pricing, Supply Level & Notes, Controls


Pricing for USA, Canada and Mexico shipping destinations View International Pricing
Order this mouse

Cryopreserved

Cryopreserved Mice - Ready for Recovery

Price (US dollars $)
Cryorecovery* $1980.00
Animals Provided

At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes for further information.

Supply Notes

  • Cryorecovery - Standard.
    We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. The total number of animals provided, their gender and genotype will vary. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 13 and 16 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.

    Cryorecovery to establish a Dedicated Supply for greater quantities of mice.
    Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).

Pricing for International shipping destinations View USA Canada and Mexico Pricing
Order this mouse

Cryopreserved

Cryopreserved Mice - Ready for Recovery

Price (US dollars $)
Cryorecovery* $2574.00
Animals Provided

At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes for further information.

Supply Notes

  • Cryorecovery - Standard.
    We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. The total number of animals provided, their gender and genotype will vary. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 13 and 16 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.

    Cryorecovery to establish a Dedicated Supply for greater quantities of mice.
    Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).

View USA Canada and Mexico Pricing View International Pricing

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes for further information.

General Supply Notes

  • This strain is included in the Induced Mutant Resource Colony collection.

Control Information

  Control
   Wild-type from the colony
 
  Considerations for Choosing Controls
  Control Pricing Information for Genetically Engineered Mutant Strains.
 

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.


See Terms of Use tab for General Terms and Conditions


The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.
Ordering Information
JAX® Mice
Surgical and Preconditioning Services
JAX® Services
Customer Services and Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form

Terms of Use

Terms of Use


General Terms and Conditions


Use of the Tet-System may require a license, see Licenses for Strains Using TET-System Technology.

Contact information

General inquiries

Contracts Administration

phone:207-288-6470
fax:207-288-6655

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.


(5.1)